Abstract
Aim. Based on scientific literature data, to evaluate the effectiveness of the use of immune checkpoint inhibitors (ICI) in the treatment of non-small cell lung cancer (NSCLC). Materials and methods. To analyze the results of clinical trials of NSCLC treatment with immune checkpoint inhibitors. Conclusions. Among the immune checkpoint inhibitors, PD-1/PD-L1 inhibitors, namely Nivolumab, Pembrolizumab and Atezolizumab, are most successful in the treatment of NSCLC. Their use significantly increases overall survival and progression-free survival with a lower profile of adverse events. They are prescribed as both second-line and first-line drugs in the NSCLC therapy. Such biomarkers as Teff gene expression level, tumor mutational load (TMB) level and interferon gamma (IFNG) mRNA expression level have also been identified. They allow to more accurately determine the group of patients who will show the best response to therapy with PD-1/ PD-L1 inhibitors.
Highlights
A – концепція та дизайн дослідження; B – збір даних; C – аналіз та інтерпретація даних; D – написання статті; E – редагування статті; F – остаточне затвердження статті
They are prescribed as both second-line and first-line drugs in the non-small cell lung cancer (NSCLC) therapy. Such biomarkers as Teff gene expression level, tumor mutational load (TMB) level and interferon gamma (IFNG) mRNA expression level have been identified. They allow to more accurately determine the group of patients who will show the best response to therapy with programmed cell death 1 (PD-1)/ PD-L1 inhibitors
[26] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial / A
Summary
Among the immune checkpoint inhibitors, PD-1/PD-L1 inhibitors, namely Nivolumab, Pembrolizumab and Atezolizumab, are most successful in the treatment of NSCLC Their use significantly increases overall survival and progressionfree survival with a lower profile of adverse events. Рак легкого (РЛ) – основная причина смерти от рака среди мужчин и вторая ведущая причина смерти от злокачественных новообразований среди женщин во всем мире [31]. В мире диагностировали 1,8 млн новых случаев заболевания раком легких, 1,6 млн из них умерли в том же году [7]. Количество случаев смерти от РЛ среди мужчин снизилось на 45 %, а число случаев смерти среди женщин – на 19 % в период 2002–2015 гг. Несмотря на прогресс в диагностике и лечении РЛ, количество больных в мире продолжает расти, в основном за счет стран Азии и Восточной Европы, в. В терапии РЛ лучшие результаты показали ИКТ [33]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
